ADB-BINACA

ADB-BINACA is a cannabinoid receptor agonist that has been used as a designer drug. It is a molecule that was originally developed by Pfizer for the treatment of pain, but was not commercially successful and is now sold as a research chemical.

Chemistry

ADB-BINACA is a synthetic cannabinoid, which means it is a chemical compound that mimics the effects of cannabinoids produced naturally by the body. It is structurally related to other synthetic cannabinoids such as AB-FUBINACA and AB-PINACA.

Pharmacology

ADB-BINACA acts as a full agonist at the CB1 receptor and the CB2 receptor, the two main cannabinoid receptors in the body. It has a high affinity for these receptors, which means it binds to them very tightly and activates them strongly. This is what gives ADB-BINACA its potent psychoactive effects.

Effects

The effects of ADB-BINACA can vary widely depending on the dose and the individual's sensitivity to cannabinoids. Some common effects include euphoria, relaxation, altered perception, and sometimes anxiety and paranoia. At high doses, ADB-BINACA can cause severe and potentially dangerous effects such as psychosis, seizures, and cardiac arrest.

Legal status

The legal status of ADB-BINACA varies by country. In the United States, it is a Schedule I controlled substance, which means it is illegal to manufacture, distribute, or possess. In other countries, it may be legal or regulated differently.

See also

• Synthetic cannabinoids
• Designer drugs
• Cannabinoid receptor

ADB-BINACA Resources
Latest articles Most recent articles Ongoing trials	Wikipedia